XORTX Therapeutics (XRTX)

• Market cap: $3.34M
• 1 day: -11.7%
• 5 days: -25.59%
• 1 month: -26.43%
• 3 months: -32.56%
• 6 months: -39.06%
• Year to date: -45.31%
• 1 year: -58.72%
• 5 years: -99.75%
• 10 years: -99.75%
• Sector: Healthcare
• Industry: Biotechnology

About: XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection, and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.

Employees: 3